0001683168-19-002184.txt : 20190715 0001683168-19-002184.hdr.sgml : 20190715 20190712191633 ACCESSION NUMBER: 0001683168-19-002184 CONFORMED SUBMISSION TYPE: NT 10-Q PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190531 FILED AS OF DATE: 20190715 DATE AS OF CHANGE: 20190712 EFFECTIVENESS DATE: 20190715 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Gala Pharmaceutical Inc. CENTRAL INDEX KEY: 0001513403 STANDARD INDUSTRIAL CLASSIFICATION: APPAREL & OTHER FINISHED PRODS OF FABRICS & SIMILAR MATERIAL [2300] IRS NUMBER: 421771014 STATE OF INCORPORATION: NV FISCAL YEAR END: 1130 FILING VALUES: FORM TYPE: NT 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-55998 FILM NUMBER: 19953840 BUSINESS ADDRESS: STREET 1: 18881 VON KARMAN AVE. STREET 2: SUITE 1440 CITY: IRVINE STATE: CA ZIP: 92612 BUSINESS PHONE: 949-851-9261 MAIL ADDRESS: STREET 1: 18881 VON KARMAN AVE. STREET 2: SUITE 1440 CITY: IRVINE STATE: CA ZIP: 92612 FORMER COMPANY: FORMER CONFORMED NAME: Gala Pharmaceuticals Inc. DATE OF NAME CHANGE: 20180202 FORMER COMPANY: FORMER CONFORMED NAME: Gala Pharmaceutical Inc. DATE OF NAME CHANGE: 20180201 FORMER COMPANY: FORMER CONFORMED NAME: Gala Global Inc. DATE OF NAME CHANGE: 20110217 NT 10-Q 1 gala_nt10q.htm

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 12b-25

 

NOTIFICATION OF LATE FILING

 

(Check one):

OMB APPROVAL  
  OMB Number: 3235-0058
Expires: August 31, 2015
Estimated average burden
hours per response.... 2.50
   
  SEC FILE NUMBER
333-172744
   
  CUSIP NUMBER
36316C106

 

[_] Form 10-K    [_] Form 20-F    [_] Form 11-K
[X] Form 10-Q    [_] Form 10-D    [_] Form N-SAR    [_] Form N-CSR

 

For Period Ended: May 31, 2019

 

[_] Transition Report on Form 10-K
[_] Transition Report on Form 20-F
[_] Transition Report on Form 11-K
[_] Transition Report on Form 10-Q
[_] Transition Report on Form N-SAR

 

For the Transition Period Ended:

 

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.


If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

 

PART I — REGISTRANT INFORMATION

 

GALA PHARMACEUTICAL INC.
Full Name of Registrant

 

N/A
Former Name if Applicable

 

18881 Von Karman Blvd., Suite 1440

Address of Principal Executive Office (Street and Number)

 

Irvine, CA 92612

City, State and Zip Code

 

 

 

 

   

 

 

 
 

PART II — RULES 12b-25(b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed.  (Check box if appropriate)

 

x (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
   
(b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
   
(c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

PART III — NARRATIVE

 

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

 

The company’s auditor will complete their review of the financial information approximately July 19, 2019.

 

PART IV — OTHER INFORMATION

 

(1) Name and telephone number of person to contact in regard to this notification

 

  Owen Naccarato 949 851-9261
  (Name) (Area Code) (Telephone Number)

 

(2)

Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed ?  If answer is no, identify report(s).

[ X ] Yes [    ] No

   
(3)

Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

[    ] Yes [ X ] No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

GALA PHARMACEUTICAL INC.
(Name of Registrant as Specified in Charter)

 

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

     
Date: July 12, 2019 By: /s/ Maqsood Rehman
    Maqsood Rehman
    Title: Chief Executive Officer

 

 

 

 2